

# Yoshito Komatsu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3147450/publications.pdf>

Version: 2024-02-01

69  
papers

6,495  
citations

218381

26  
h-index

102304

66  
g-index

69  
all docs

69  
docs citations

69  
times ranked

7134  
citing authors

#	ARTICLE	IF	CITATIONS
1	Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 1224-1235.	5.1	1,932
2	Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer. <i>New England Journal of Medicine</i> , 2015, 372, 1909-1919.	13.9	1,027
3	Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. <i>Lancet</i> , The, 2018, 392, 123-133.	6.3	984
4	Phase II Study of Chemoradiotherapy With 5-Fluorouracil and Cisplatin for Stage IIâ€“III Esophageal Squamous Cell Carcinoma: JCOG Trial (JCOG 9906). <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, 684-690.	0.4	303
5	Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2013, 14, 1278-1286.	5.1	227
6	Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies. <i>Nature Medicine</i> , 2020, 26, 1859-1864.	15.2	209
7	Multicenter Phase II Study of Everolimus in Patients With Previously Treated Metastatic Gastric Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 1904-1910.	0.8	195
8	Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS) <i>Tj ETQq0 0 0 rgBT /Overlook 10 Tf 5</i>		
9	Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial. <i>Nature Medicine</i> , 2021, 27, 1899-1903.	15.2	110
10	Clinical Relevance of the babA2 Genotype of <i>Helicobacter pylori</i> in Japanese Clinical Isolates. <i>Journal of Clinical Microbiology</i> , 2001, 39, 2463-2465.	1.8	107
11	Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations. <i>Investigational New Drugs</i> , 2015, 33, 740-750.	1.2	94
12	Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer. <i>Gastric Cancer</i> , 2015, 18, 824-832.	2.7	91
13	Phase 2 study of nilotinib as thirdâ€“line therapy for patients with gastrointestinal stromal tumor. <i>Cancer</i> , 2011, 117, 4633-4641.	2.0	76
14	Endoscopic clip application for closure of esophageal perforations caused by EMR. <i>Gastrointestinal Endoscopy</i> , 2004, 60, 636-639.	0.5	64
15	Preoperative Chemoradiotherapy plus Nivolumab before Surgery in Patients with Microsatellite Stable and Microsatellite Instabilityâ€“High Locally Advanced Rectal Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1136-1146.	3.2	62
16	Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate. <i>Investigational New Drugs</i> , 2010, 28, 866-875.	1.2	58
17	Sunitinib-resistant gastrointestinal stromal tumors harbor cis-mutations in the activation loop of the KIT gene. <i>International Journal of Clinical Oncology</i> , 2009, 14, 143-149.	1.0	57
18	Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer. <i>Cancer Science</i> , 2011, 102, 425-431.	1.7	51

#	ARTICLE	IF	CITATIONS
19	Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study. <i>European Journal of Cancer</i> , 2020, 129, 97-106.	1.3	48
20	Multicenter Phase I/II Trial of Napabucasin and Pembrolizumab in Patients with Metastatic Colorectal Cancer (EPOC1503/SCOOP Trial). <i>Clinical Cancer Research</i> , 2020, 26, 5887-5894.	3.2	44
21	Phase I/II Study of Capecitabine Plus Oxaliplatin (XELOX) Plus Bevacizumab As First-line Therapy in Japanese Patients with Metastatic Colorectal Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2010, 40, 913-920.	0.6	40
22	Multicenter Phase II Study of Cetuximab Plus Irinotecan in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin and Fluoropyrimidines. <i>Japanese Journal of Clinical Oncology</i> , 2008, 38, 762-769.	0.6	33
23	Eradication of <i>Helicobacter pylori</i> for primary gastric cancer and secondary gastric cancer after endoscopic mucosal resection. <i>Journal of Gastroenterology</i> , 2007, 42, 16-20.	2.3	32
24	Phase II trial of aflibercept with FOLFIRI as a second-line treatment for Japanese patients with metastatic colorectal cancer. <i>Cancer Science</i> , 2019, 110, 1032-1043.	1.7	30
25	Long-term treatment of localized gastric marginal zone B-cell mucosa associated lymphoid tissue lymphoma including incidence of metachronous gastric cancer. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 804-809.	1.4	28
26	Regorafenib for advanced gastrointestinal stromal tumors following imatinib and sunitinib treatment: a subgroup analysis evaluating Japanese patients in the phase III GRID trial. <i>International Journal of Clinical Oncology</i> , 2015, 20, 905-912.	1.0	27
27	Circulating Tumor DNA Analysis Detects FGFR2 Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5619-5627.	3.2	27
28	A phase 3 non-inferiority study of 5-FU/leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer: updated results of the FIRIS study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 153-160.	1.2	26
29	Phase 1 study of efatutazone, a novel oral peroxisome proliferator-activated receptor gamma agonist, in combination with FOLFIRI as second-line therapy in patients with metastatic colorectal cancer. <i>Investigational New Drugs</i> , 2014, 32, 473-480.	1.2	25
30	Phase II Study of Combined Treatment with Irinotecan and S-1 (IRIS) in Patients with Inoperable or Recurrent Advanced Colorectal Cancer (HGCSG0302). <i>Oncology</i> , 2011, 80, 70-75.	0.9	22
31	Phase II study of combined chemotherapy with irinotecan and S-1 (IRIS) plus bevacizumab in patients with inoperable recurrent or advanced colorectal cancer. <i>Acta Oncologica</i> , 2012, 51, 867-872.	0.8	20
32	Decreased Adherence of cagG-Deleted <i>Helicobacter pylori</i> to Gastric Epithelial Cells in Japanese Clinical Isolates. <i>Helicobacter</i> , 2002, 7, 22-29.	1.6	17
33	Phase I/2 clinical study of irinotecan and oral S-1 (IRIS) in patients with advanced gastric cancer. <i>Advances in Therapy</i> , 2010, 27, 483-492.	1.3	16
34	Randomized phase II trial of first-line treatment with tailored irinotecan and S-1 therapy versus S-1 monotherapy for advanced or recurrent gastric carcinoma (JFMC31-0301). <i>Anti-Cancer Drugs</i> , 2011, 22, 576-583.	0.7	16
35	Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines. <i>Investigational New Drugs</i> , 2012, 30, 787-793.	1.2	16
36	Association between the use of antibiotics and efficacy of gemcitabine plus nab-paclitaxel in advanced pancreatic cancer. <i>Medicine (United States)</i> , 2020, 99, e22250.	0.4	14

#	ARTICLE	IF	CITATIONS
37	Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer. <i>BMC Cancer</i> , 2015, 15, 626.	1.1	13
38	Safety, efficacy and prognostic analyses of sunitinib in the post-marketing surveillance study of Japanese patients with gastrointestinal stromal tumor. <i>Japanese Journal of Clinical Oncology</i> , 2015, 45, 1016-1022.	0.6	13
39	Treatment Pattern for Advanced Gastric Cancer in Japan and Factors Associated with Sequential Treatment: A Retrospective Administrative Claims Database Study. <i>Advances in Therapy</i> , 2022, 39, 296-313.	1.3	13
40	Phase II study of motesanib in Japanese patients with advanced gastrointestinal stromal tumors with prior exposure to imatinib mesylate. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 65, 961-967.	1.1	12
41	An Investigator-Initiated Phase 2 Study of Nivolumab Plus Low-Dose Ipilimumab as First-Line Therapy for Microsatellite Instability-High Advanced Gastric or Esophagogastric Junction Cancer (NO LIMIT, Tj ETQq1 1 0.7843 14 rgB11/Overlock	1.1	11
42	Retrospective Cohort Study on the Safety and Efficacy of Bevacizumab with Chemotherapy for Metastatic Colorectal Cancer Patients: The HGCSG0801 Study. <i>Japanese Journal of Clinical Oncology</i> , 2011, 41, 490-497.	0.6	9
43	A Randomized Phase II Clinical Trial of Tailored CPT-11 + S-1 vs S-1 in Patients with Advanced or Recurrent Gastric Carcinoma as the First Line Chemotherapy. <i>Japanese Journal of Clinical Oncology</i> , 2004, 34, 342-345.	0.6	8
44	Phase II Study of Ramucirumab Plus Irinotecan Combination Therapy as Second-Line Treatment in Patients with Advanced Gastric Cancer: HGCSG1603. <i>Oncologist</i> , 2022, 27, e642-e649.	1.9	8
45	Randomized Phase II Study Comparing Dose Escalated Weekly Paclitaxel vs. Standard Dose Weekly Paclitaxel for Patients with Previously Treated Advanced Gastric Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2011, 41, 287-290.	0.6	7
46	Intense F-18 FDG Accumulation in the Stomach in a Patient with Menetrier's Disease. <i>Clinical Nuclear Medicine</i> , 2002, 27, 376-377.	0.7	7
47	The SOFT trial: a Phase III study of the dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine S-1 and oxaliplatin (SOX) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer. <i>Future Oncology</i> , 2015, 11, 1471-1478.	1.1	6
48	Phase II Study of Oral S-1 Plus Irinotecan in Patients with Advanced Colorectal Cancer: Hokkaido Gastrointestinal Cancer Study Group HGCSG0302. <i>Japanese Journal of Clinical Oncology</i> , 2005, 35, 88-89.	0.6	5
49	Pilot Study of Combination Chemotherapy Using Irinotecan plus S-1 for Metastatic Pancreatic Cancer. <i>Oncology</i> , 2008, 75, 67-70.	0.9	5
50	Modified-Irinotecan/Fluorouracil/Levoleucovorin Therapy as Ambulatory Treatment for Metastatic Colorectal Cancer. <i>Clinical Drug Investigation</i> , 2010, 30, 243-249.	1.1	5
51	Validation study of a prognostic classification in patients with metastatic colorectal cancer who received irinotecan-based second-line chemotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 595-603.	1.2	5
52	Study protocol of HGCSG1404 SNOW study: a phase I/II trial of combined chemotherapy of S-1, nab-paclitaxel and oxaliplatin administered biweekly to patients with advanced gastric cancer. <i>BMC Cancer</i> , 2017, 17, 837.	1.1	5
53	Advanced colorectal cancer subtypes (aCRCS) help select oxaliplatin-based or irinotecan-based therapy for colorectal cancer. <i>Cancer Science</i> , 2021, 112, 1567-1578.	1.7	5
54	Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label, phase III, non-inferiority trial. <i>European Journal of Cancer</i> , 2021, 154, 296-306.	1.3	5

#	ARTICLE	IF	CITATIONS
55	Impact of sex and histology on the therapeutic effects of fluoropyrimidines and oxaliplatin plus bevacizumab for patients with metastatic colorectal cancer in the SOFT trial. <i>Global Health &amp; Medicine</i> , 2020, 2, 240-246.	0.6	4
56	Prognostic biomarker study in patients with clinical stage I esophageal squamous cell carcinoma: JCOG0502. <i>Cancer Science</i> , 2022, 113, 1018-1027.	1.7	4
57	Rapid Screening Using Pathomorphologic Interpretation to Detect <i>BRAF</i> V600E Mutation and Microsatellite Instability in Colorectal Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 2623-2632.	3.2	4
58	Phase II Study of Combination Chemotherapy with Biweekly Cetuximab and Irinotecan for Pre-treated Metastatic Colorectal Cancer Harboring Wild-type KRAS. <i>Japanese Journal of Clinical Oncology</i> , 2010, 40, 699-701.	0.6	3
59	A Phase I Trial of Oxaliplatin, Irinotecan, and S-1 Combination Therapy (OX-IRIS) as Chemotherapy for Unresectable Pancreatic Cancer (HGCSG 1403). <i>Oncologist</i> , 2021, 26, e1675-e1682.	1.9	3
60	Analysis of the Pancreatic Cancer Microbiome Using Endoscopic Ultrasound-Guided Fine-Needle Aspiration-Derived Samples. <i>Pancreas</i> , 2022, 51, 351-357.	0.5	3
61	TiFFANY study: A multicenter phase II basket-type clinical trial to evaluate efficacy and safety of pan-FGFR inhibitor TAS-120 for advanced solid malignancies with FGFR alterations identified by circulating tumor DNA. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS3156-TPS3156.	0.8	2
62	Multicenter, prospective, observational study of chemotherapy-induced dysgeusia in gastrointestinal cancer. <i>Supportive Care in Cancer</i> , 2022, , 1.	1.0	2
63	Sensitivity to previous irinotecan treatment does not predict the efficacy of combination chemotherapy with cetuximab plus irinotecan for wild-type KRAS metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2011, 47, 2673-2680.	1.3	1
64	Impact of single-heterozygous UGT1A1 on the clinical outcomes of irinotecan monotherapy after fluoropyrimidine and platinum-based combination therapy for gastric cancer: a multicenter retrospective study. <i>International Journal of Clinical Oncology</i> , 2020, 25, 1800-1806.	1.0	1
65	Factors associated with treatment duration from start of second-line ramucirumab plus paclitaxel or nab-PTX for advanced gastric cancer: real-world evidence from Japanese Claim Database. <i>Journal of Clinical Oncology</i> , 2021, 39, 177-177.	0.8	1
66	Impact of tumor growth rate during preceding treatment on tumor response to nivolumab or irinotecan in advanced gastric cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 84-84.	0.8	1
67	Study protocol of the HGCSG1803: a phase II multicentre, non-randomised, single-arm, prospective trial of combination chemotherapy with oxaliplatin, irinotecan and S-1 (OX-IRIS) as first-line treatment for metastatic or relapsed pancreatic cancer. <i>BMJ Open</i> , 2022, 12, e048833.	0.8	1
68	H. Pylori eradication for the prevention of metachronous gastric cancer after endoscopic resection of early gastric cancer. <i>Gastroenterology</i> , 2001, 120, A744.	0.6	0
69	Safeness and Usefulness of Endoscopic Submucosal Dissection (ESD) Versus Conventional EMR for Superficial Gastric Lesions. <i>Gastrointestinal Endoscopy</i> , 2007, 65, AB181.	0.5	0